Categories: Immuno oncology

Expert Says Much Can Be Learned From Older, Simpler Research in Colorectal Cancer

In 2015, the FDA approvals of Cyramza (ramucirumab) and Lonsurf (TAS-102 ) led to updates to the NCCN treatment guidelines for colorectal ca...

When it comes to being deaf in a hearing world, a recipe for success is to simply have “chutzpah,” and the same can be said for...

Treatment with Rintega (rindopepimut) plus temozolomide failed to improve overall survival (OS) compared with temozolomide and a control for...

It has been an "embarrassment of riches" in the treatment paradigm for patients with non–small cell lung cancer (NSCLC)...

Patients with advanced renal cell carcinoma (RCC) now have more second-line treatment options. In fact, the FDA recently approved Opdivo (ni...

For years, brain cancer has been difficult to treat. After letdowns in prior research, immunotherapeutics and novel targeted therapy are pro...

Research into immunotherapy for non–small cell lung cancer (NSCLC) is progressing rapidly according to Naiyer Rizvi, and is unlikely t...

Robert Ferris has been trying for years to harness the immune system to fight cancer. “Since I got my MD/PhD 25 years ago in immunolo...

An affinity enhanced T-cell therapy has received an FDA breakthrough therapy designation for the treatment of patients with inoperable or me...

The combination of Opdivo (nivolumab) and radiation therapy may provide better disease control and a boost in overall survival (OS) in patie...